Corporate Earnings Highlight Q4 and Q3 Results; Geopolitical and Macroeconomic Factors Monitored

By / / Breaking News

Key Takeaways

  • Philip Morris International (PM) reported a strong Q4 adjusted EPS of $7.54, significantly surpassing the estimated $1.70, but announced no share repurchases in 2026.
  • Under Armour (UAA, UA) posted a Q3 net loss of $431 million with an EPS of -$1.01, though its adjusted EPS of $0.09 beat analyst estimates of -$0.02.
  • China has approved some rare earth exports to Japan, a development that could ease tensions in critical mineral supply chains.
  • The Euro's strength has drawn attention from the European Central Bank (ECB), raising concerns about currency-driven disinflation and its potential impact on the EURUSD exchange rate.
  • Pfizer (PFE) awaits an FDA PDUFA action date for HYMPAVZI in Q2 2026.

Corporate Earnings: Philip Morris and Under Armour Report

Philip Morris International (PM) delivered robust Q4 2025 adjusted earnings per share (EPS) of $7.54, significantly exceeding the analyst estimate of $1.70. The tobacco giant also reported Q4 revenue of $10.4 million, falling short of the estimated $10,440 million. Looking ahead, the company forecasts full-year adjusted EPS for FY 2026 to be between $8.38 and $8.53 and anticipates first-quarter adjusted diluted EPS of $1.80 to $1.85. Notably, Philip Morris stated it sees no share repurchases in 2026, a decision that may impact investor sentiment regarding capital allocation. The company declared a Q4 dividend of $1.47.

Under Armour (UAA, UA) released its Q3 2026 results, revealing a gross margin of 44.4%. The athletic apparel and footwear company reported a net loss of $431 million, translating to an EPS of -$1.01. Despite the significant net loss, Under Armour's adjusted net income stood at $37 million, with an adjusted EPS of $0.09, which surpassed the estimated -$0.02. The company's Q3 EBIT was -$150 million.

Global Trade and Macroeconomic Shifts

In a significant development for global supply chains, China has approved some rare earth exports to Japan. This move comes amidst ongoing efforts by Japan to reduce its reliance on Chinese rare earth supplies and diversify its critical mineral sources. The decision could be interpreted as a step towards easing trade tensions in this strategically important sector.

Meanwhile, the Euro's strength has become a focal point for the European Central Bank (ECB). The trade-weighted euro is currently at multi-decade highs, prompting questions about how long the ECB can overlook currency-driven disinflation. Any indication that inflation risks are trending lower due to a strong euro could potentially weigh on the EURUSD exchange rate.

Pharmaceutical Sector Update

Pfizer (PFE) announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA (Prescription Drug User Fee Act) action date for HYMPAVZI in Q2 2026. This regulatory milestone is crucial for the potential approval and market availability of the drug, which is being evaluated for hemophilia A or B.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top